Engineers Gate Manager LP Cytom X Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $655 - $1,052	-551 Reduced 5.16%	10,135 $16,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $20,821 - $33,348	-16,928 Reduced 61.3%	10,686 $15,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $137 - $260	90 Added 0.33%	27,614 $51,000
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $110,615 - $193,887	-41,429 Reduced 60.08%	27,524 $73,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $266,848 - $509,562	68,953 New	68,953 $299,000
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $237,751 - $353,875	-55,035 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $161,636 - $253,051	25,535 Added 86.56%	55,035 $348,000
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $194,700 - $265,500	29,500 New	29,500 $228,000
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $183,806 - $224,431	-28,409 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$6.55 - $8.83 $115,129 - $155,204	-17,577 Reduced 38.22%	28,409 $189,000
Q2 2020 Aug 17, 2020	BUY	$7.4 - $14.64 $242,616 - $479,987	32,786 Added 248.38%	45,986 $383,000
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $47,652 - $113,520	13,200 New	13,200 $101,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.